Home News Insights Trading halts Paper trading Guide Community My account

Market calendarNext market opening

Display in USD

Loading news article.

U.S. stock guide
Scanner guide
Paper trading guide
Terms of service
Privacy policy
Announcements
FAQ

Support: help@wapeb.comPartnerships: partnership@wapeb.com

WAPE is a free research, analysis and paper trading service. It does not place real securities orders. Market data and AI summaries are for information only, not investment advice or stock recommendations. Information may include delays, errors or estimates. Check original sources and supporting materials. You are responsible for your investment decisions and any resulting gains or losses.

Language한국어 English

Loading news article.

Clinuvel Pharmaceuticals Files Marketing Authorisation Dossier for NEURACTHEL® Instant in Europe | WAPE

Back All news

Newsfiscal.ai

Clinuvel Pharmaceuticals Files Marketing Authorisation Dossier for NEURACTHEL® Instant in Europe

Oct 30, 2026, 18:02 ET · Published

View source

Article summary

Clinuvel Pharmaceuticals has submitted a marketing authorisation dossier for its second pharmaceutical product, NEURACTHEL® Instant (tetracosactide), to European regulators via the decentralised procedure.

An excerpt from the original article.

Related companies

Clinuvel Pharmaceuticals Limited American Depositary SharesCUVLView stock

Clinuvel Pharmaceuticals Files Marketing Authorisation Dossier for NEURACTHEL® Instant in Europe

Article summary

Related companies

Analyzed by WAPE AI.

Comments —